

Development of an Diagnostic Antibiotic Stewardship (ABS) Strategy combining Therapeutic Drug Monitoring (TDM) with Culture-Independent Fast Antimicrobial Susceptibility Testing (AST) in Patients Suffering From Pneumonia

Matthias Karrasch, Sophie Neugebauer, Sibylle Bremer-Streck, Michael Kiehntopf

Institute of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, Jena, Germany

Introduction:

- Fast antimicrobial susceptibility testing (AST), minimal inhibitory concentration (MIC) detection and therapeutic drug monitoring (TDM) with consecutive adapted antibiotic drug dosing is of vital importance for clinical outcome in patients suffering from pneumonia.

What is „Diagnostic Stewardship“ ?: coordinated guidance and interventions to improve appropriate use of microbiological diagnostics to guide therapeutic decisions. It should promote appropriate, timely diagnostic testing, including specimen collection, and pathogen identification and accurate, timely reporting of results to guide patient treatment



Methods (1):


- At ECCMID 2018, we reported very promising evaluation results for a new, fully automated, culture-independent diagnostic FISH/ microscopy-based method used for pathogen identification (ID), antimicrobial susceptibility testing (AST) and minimal inhibitory concentration (MIC) detection (Accelerate Pheno™, Tucson, AZ, USA) in patients suffering from sepsis (1)
- Susceptibility reports are generated by microscopic observation of individual, live, growing immobilized bacterial cells in real time in the presence/absence (control) of antimicrobial agents.
- Antimicrobials for AST are selected based on the respective identified pathogen.

Methods (2):

- High-performance liquid chromatography (HPLC) using UV detection is frequently used for TDM.
- We developed a more sensitive and selective method using HPLC coupled with tandem mass spectrometry (LC-MS/MS) for TDM of eight antimicrobials (ampicillin, cefuroxime, ciprofloxacin, meropenem, metronidazole, piperacillin, rifampicin, tazobactam) plus one nucleoside antiviral drug (acyclovir) in lithium-heparin plasma with a chromatographic run time of ten minutes (2).
- Analyses were performed using an Agilent 1200 series system (Santa Clara, CA), consisting of a thermostatic autosampler, a binary solvent delivery manager, and a thermostated column compartment. Chromatographic separation was achieved using a Kinetex F5 core-shell reverse-phase column (50 × 2.1 mm, 100 Å pore size, 2.6 µm particle size; Phenomenex, Aschaffenburg, Germany) and a corresponding F5 precolumn with a 2.1-mm internal diameter (Phenomenex, Aschaffenburg, Germany).
- detection was conducted with an API4000 LC-MS/MS System (AB SCIEX, Framingham, MA) equipped with an electrospray ionization source.

Multipurpose reagent cartridge design

- 100 pipette tips
- Over 150 wells for antimicrobials, media, reagents, probes, and waste
- 2 Gel Electro-Filtration wells for sample prep



Enterobacter spp.
Proteus spp.
Citrobacter spp.
S. marcescens
P. aeruginosa
A. baumannii
C. albicans
C. glabrata

S. aureus
S. lugdunensis
CoNS spp.
E. faecium
E. faecalis
Streptococcus spp.
E. coli
Klebsiella spp.

Fig. 1: Cartridge design & FISH-based pathogen ID

sample preparation





Fig. 3: Sample preparation (left) and representative MRM chromatograms (right). The peaks are shown in an overall overview of positive and negative ionization, including retention times in a sample MRM chromatogram for 10 mg/L of antimicrobials in lithium-heparin plasma. Left panel: MRM chromatogram of all antimicrobials (quantifier) with positive ionization, Right panel: MRM chromatogram of all antimicrobials (quantifier) with negative ionization.

Conclusion:

- Development of an Diagnostic Antibiotic Stewardship Strategy: We aim to combine the LC-MS/MS based TDM method with the FISH/microscopy-based ID/AST method to have a more personalized therapeutic drug dosing approach for patients suffering from pneumonia in a clinical study.

Acknowledgements:

- BMBF grant 01EO1002 (“Center for Sepsis Control and Care”) SMARTDOSE : Simultaneous determination of multiple antibiotics by LC-MS/MS for personalized antibiotic treatment
- Malcolm Boswell, Natalia Duarte, Diederik Engbersen, Roman Hopkins, Torsten Neumann, Wolfgang Scharf; Accelerate Diagnostics Inc., Tucson, AZ, USA; Accelerate Diagnostics GmbH, Hamburg, Germany; Accelerate Diagnostics S.L., Castelldefels, Barcelona, Spain

References:


- Karrasch M, Bender M, Geraci J, Rödel J, Brunkhorst F, Löffler B. Accelerating time-to-pathogen-adapted antibiotic treatment through subculture-independent phenotypic AST in patients suffering from sepsis. ECCMID 2018, P1796, Session: Rapid antimicrobial susceptibility testing
- Neugebauer S, Wichmann C, Bremer-Streck S, Hagel S, Kiehntopf M. Simultaneous Quantification of Nine Antimicrobials by LC-MS/MS for Therapeutic Drug Monitoring in Critically Ill Patients. *Ther Drug Monit.* 2018;41(1):29–37. doi:10.1097/FTD.0000000000000570




Abstract Number: P2064

Session name: Two sides of a coin: diagnostic and antimicrobial stewardship
Date/time: 15 April 2019, 1.30 p.m. - 2.30 p.m.


Automated Sample Preparation



Identification & Quantitation



Susceptibility Analysis and Reporting



GPU Image Computation & Proprietary Machine Learning Algorithms




Fig. 2: Identification, quantification & morphokinetic cellular analysis: Distinct morphokinetic features are translated into a growth response profile and converted to a Minimum Inhibitory Concentration (MIC) value